期刊文献+

HPLC法测定利伐沙班有关物质 被引量:7

Determination of rivaroxaban related substances by HPLC
原文传递
导出
摘要 目的建立HPLC法测定利伐沙班原料药的有关物质。方法采用Purospher Star RP-18endcapped(55mm×4.0mm,3μm)色谱柱;10mmol·L-1磷酸为流动相A,乙腈为流动相B,梯度洗脱;进样量为5μL;检测波长为250nm;流速为1.0mL·min-1;柱温为45℃。结果利伐沙班及各杂质能得到良好的分离,3批样品中单一杂质的含量质量分数均小于0.1%。结论该方法可用于利伐沙班原料药中有关物质的检测。 Objective To develop an HPLC method for determination of rivaroxaban related substances. Methods The chromatographic column was Purospher Star RP- 18endcapped(55 nun × 4.0 mm,3 m). The mobile phase A was 10 mmol·L-1 phosphate acid and acetonitrile was the mobile phase B. A gradient elution was used at a flow rate of 1.0 mL· min-1. The injection volume was 5 μL and the detection wave- length was at 250 nm. The column temperature was 45 ℃. Results The separation of rivaroxaban and its re- lated compounds are good. The impurities have been found with levels below 0.1% (w) in the drug sub- stance. Conclusions The method can be used for the determination of rivaroxaban related substances in rivaroxaban materials.
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2015年第8期627-632,共6页 Journal of Shenyang Pharmaceutical University
关键词 利伐沙班 高效液相色谱法 有关物质 检测 rivaraxaban HPLC related substances detection
  • 相关文献

参考文献2

二级参考文献19

  • 1Friedman RJ,Dahl OE,Rosencher N,et al.Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty:a pooled analysis of three trials[J].Thromb Res,2010,126(3):175-182.
  • 2Eriksson BI,Dahl OE,Huo MH,et al.Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*)[J].Thromb Haemost,2011,105(4):721-729.
  • 3Schulman S,Kearon C,Kakkar AK,et al.Dabigatran versus warfarin in the treatment of acute venous thromboembolism[J].N Engl J Med,2009,361(24):2342-2352.
  • 4Connolly SJ,Ezekowitz MD,Yusuf S,et al.Dabigatran versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2009,361(12):1139-1151.
  • 5Wann LS,Curtis AB,Ellenbogen KA,et al.2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran):a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J].Circulation,2011,123(10):1144-1150.
  • 6Oldgren J,Budaj A,Granger CB,et al.Dabigatran vs.placebo in patients with acute coronary syndromes on dual antiplatelet therapy:a randomized,double-blind,phase II trial[J].Eur Heart J,2011,32(22):2781-2789.
  • 7Eriksson BI,Borris LC,Friedman RJ,et al.Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty[J].N Engl J Med,2008,358(26):2765-2775.
  • 8Kakkar AK,Brenner B,Dahl OE,et al.Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty:a double-blind,randomised controlled trial[J].Lancet,2008,372(9632):31-39.
  • 9Lassen MR,Ageno W,Borris LC,et al.Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty[J].N Engl J Med,2008,358(26):2776-2786.
  • 10Turpie AG,Lassen MR,Davidson BL,et al.Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4):a randomised trial[J].Lancet,2009,373(9676):1673-1680.

共引文献22

同被引文献23

引证文献7

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部